Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 3Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Tongue Neoplasms 1Sturge-Weber Syndrome 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Port-Wine Stain 1Peutz-Jeghers Syndrome 1Neuroendocrine Tumors 1Neoplastic Processes 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Liver Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioma 1Glaucoma 1Epilepsy 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Renal Cell 1

Interventions

Dexamethasone 45Bortezomib 19Lenalidomide 18Calcium Dobesilate 18Melphalan 16Cyclophosphamide 11pomalidomide 10daratumumab 9elotuzumab 8carfilzomib 8pembrolizumab 6ixazomib 6fludarabine phosphate 6dexamethasone acetate 6fludarabine 5dexamethasone 21-phosphate 5Filgrastim 5venetoclax 4selinexor 4auricularum 4Thalidomide 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4liposomal doxorubicin 3Whole-Body Irradiation 3Vorinostat 3Nivolumab 3Mycophenolic Acid 3Leukapheresis 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Multiple Myeloma × Everolimus × Clear all
NCT01234974 2013-01-10

IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus

Milton S. Hershey Medical Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡